Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib in Recurrent Malignant Glioma and Meningioma
NCT00045110Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Aug 2002
- Primary completion
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of erlotinib in malignant glioma, meningioma and glioblastoma (GBM) (2 arms), sponsored by National Cancer Institute. Primary endpoints: Dose Limiting Toxicity at 28 days, Maximum Tolerated Dose at 28 days and 1 more. Started Aug 2002; status: completed.
02
Drugs
erlotinib
03
Conditions
malignant gliomameningiomaglioblastoma (GBM)
Beyond the preview
Go deeper on NCT00045110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00045110.